Kyongbo Pharmaceutical Co., Ltd (KRX:214390)
South Korea
· Delayed Price · Currency is KRW 5,550.00
-30.00 (-0.54%)
At close: Apr 23, 2025, 3:30 PM KST
Kyongbo Pharmaceutical Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | 4,639 | 2,974 | 610.59 | -7,495 | 9,404 | Upgrade
|
| Depreciation & Amortization | 12,408 | 11,699 | 11,936 | 12,757 | 12,588 | Upgrade
|
| Loss (Gain) From Sale of Assets | 6.29 | 11.08 | -121.98 | -58.68 | 592.7 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | -43.11 | - | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | 130 | 228.13 | 134.66 | 3,836 | -8,072 | Upgrade
|
| Loss (Gain) on Equity Investments | 1,376 | 376.33 | 463.72 | 85.58 | 220.73 | Upgrade
|
| Provision & Write-off of Bad Debts | 397.06 | 186.82 | - | - | 1,303 | Upgrade
|
| Other Operating Activities | -374.74 | 3,093 | 57.45 | -2,099 | 8,219 | Upgrade
|
| Change in Accounts Receivable | 4,466 | -6,243 | -3,152 | 4,700 | -2,329 | Upgrade
|
| Change in Inventory | -17,810 | -16,280 | -274.29 | 3,933 | -380.18 | Upgrade
|
| Change in Accounts Payable | -8,079 | 8,256 | -1,562 | 2,097 | -960.46 | Upgrade
|
| Change in Other Net Operating Assets | 2,991 | 586.16 | 2,034 | 212.73 | 209.43 | Upgrade
|
| Operating Cash Flow | 149.12 | 4,844 | 10,127 | 17,968 | 20,795 | Upgrade
|
| Operating Cash Flow Growth | -96.92% | -52.16% | -43.64% | -13.60% | -12.14% | Upgrade
|
| Capital Expenditures | -12,697 | -9,693 | -12,874 | -17,506 | -12,056 | Upgrade
|
| Sale of Property, Plant & Equipment | 17.86 | 21.88 | 272.27 | 101.9 | 75.81 | Upgrade
|
| Sale (Purchase) of Intangibles | -478.46 | -949.21 | -310.13 | -817.33 | -380.24 | Upgrade
|
| Investment in Securities | -749.48 | -3,183 | -1,680 | 2,123 | -7,197 | Upgrade
|
| Other Investing Activities | -726 | -464.64 | -285.81 | -74.59 | -119.96 | Upgrade
|
| Investing Cash Flow | -14,633 | -14,268 | -14,877 | -16,174 | -19,678 | Upgrade
|
| Short-Term Debt Issued | 184,082 | 144,266 | 148,765 | 145,265 | 154,429 | Upgrade
|
| Total Debt Issued | 184,082 | 144,266 | 148,765 | 145,265 | 154,429 | Upgrade
|
| Short-Term Debt Repaid | -167,941 | -135,050 | -140,098 | -151,259 | -146,825 | Upgrade
|
| Long-Term Debt Repaid | -1,078 | -861.44 | -882.17 | -837.12 | -794.6 | Upgrade
|
| Total Debt Repaid | -169,019 | -135,911 | -140,981 | -152,097 | -147,620 | Upgrade
|
| Net Debt Issued (Repaid) | 15,063 | 8,354 | 7,784 | -6,831 | 6,809 | Upgrade
|
| Dividends Paid | -1,195 | -1,195 | -1,195 | -2,391 | -2,391 | Upgrade
|
| Other Financing Activities | - | -0 | -0 | - | 0 | Upgrade
|
| Financing Cash Flow | 13,868 | 7,159 | 6,589 | -9,222 | 4,418 | Upgrade
|
| Foreign Exchange Rate Adjustments | 266.24 | 392.98 | 219.91 | 278.45 | -865.23 | Upgrade
|
| Net Cash Flow | -349.31 | -1,871 | 2,058 | -7,149 | 4,670 | Upgrade
|
| Free Cash Flow | -12,547 | -4,849 | -2,747 | 461.73 | 8,739 | Upgrade
|
| Free Cash Flow Growth | - | - | - | -94.72% | 189.47% | Upgrade
|
| Free Cash Flow Margin | -5.26% | -2.24% | -1.40% | 0.27% | 4.06% | Upgrade
|
| Free Cash Flow Per Share | -524.69 | -202.15 | -114.90 | 19.34 | 365.19 | Upgrade
|
| Cash Interest Paid | 4,312 | 3,407 | 1,551 | 1,190 | 1,312 | Upgrade
|
| Cash Income Tax Paid | 208.49 | 200.92 | 5.29 | 976.16 | 152.93 | Upgrade
|
| Levered Free Cash Flow | -13,901 | -6,351 | -5,058 | 904.92 | 7,333 | Upgrade
|
| Unlevered Free Cash Flow | -11,220 | -4,225 | -4,014 | 1,640 | 8,150 | Upgrade
|
| Change in Net Working Capital | 16,987 | 8,747 | 3,636 | -11,347 | -2,585 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.